|
Oct 10
|
Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit
|
|
Oct 9
|
Ocugen Inc (OCGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
|
|
Oct 9
|
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial
|
|
Oct 2
|
Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa
|
|
Sep 9
|
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
|
|
Jul 29
|
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
|
|
Jul 25
|
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
|
|
Jun 24
|
Is Ocugen (OCGN) Stock Outpacing Its Medical Peers This Year?
|
|
Jun 21
|
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
|
|
May 15
|
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
|
|
May 15
|
Ocugen Inc (OCGN) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances Amid ...
|
|
May 15
|
Q1 2024 Ocugen Inc Earnings Call
|
|
May 14
|
Ocugen Provides Business Update with First Quarter 2024 Financial Results
|
|
May 10
|
Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
|
|
May 10
|
Ocugen to Present at May 2024 Investor Conferences
|
|
May 8
|
Millionaire Blueprint: 3 Stocks Under $5 With Massive Growth Potential by 2028
|
|
May 3
|
Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
|
|
May 2
|
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
|
|
Apr 29
|
Can Ocugen Stock Keep Churning Higher?
|
|
Apr 29
|
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
|